Received: 11 August 2017
Accepted: 4 December 2018
First Online: 29 December 2018
Ethics approval and consent to participate
: The ethics committee of Ulm University approved the NEONAX-trial as leading ethics committee for all German sites. In addition, local ethics committees approved the participating sites. The trial is registered withExternalRef removed(NCT02047513) and the European Clinical Trials Database (2013–005559-34). All patients signed informed consent according to GCP.
: Not applicable.
: Gemcitabine and nab-Paclitaxel were provided by Celgene. Otherwise, the authors declare no conflicts of interest. The trial was sponsored by Celgene.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.